Application Serial No.: 10/801,608 Inventor(s): Allegrini et al.

Attorney Docket No.: 100506-00023

II. AMENDMENTS TO THE CLAIMS

Claim 1. (Original) A process for the oxidation of thioethers to sulfoxides or sulfones or for the oxidation of sulfoxides to sulfones by treatment of thioethers or sulfoxides with an oxidizing amount of ϵ -phthalimidoperhexanoic acid.

Claim 2. (Original) A process as claimed in claim 1, wherein a thioether is oxidized to sulfoxide and a sulfoxide is oxidized to sulfone, wherein ε -phthalimidoperhexanoic acid is used in amount ranging from 0.8 to 1.5 equivalents per equivalent of substrate.

Claim 3. (Currently Amended) A process as claimed in claim 1, wherein a thioeter thioether is oxidized to a sulfone, wherein ε -phthalimidoperhexanoic acid is used in amounts ranging from 1.5 to 3 equivalents per equivalent of substrate.

Claim 4. (Currently Amended) A process as claimed in claim 1, wherein the oxidation is carried out at a temperature ranging from -20°C to the reflux temperature of the solvent a solvent, for a reaction time ranging from 0.5 to 24 hours.

Claim 5. (Currently Amended) A process as claimed in claim 1, wherein the oxidation is carried out in a water-miscible water-miscible or immiscible immiscible, protic or aprotic organic solvent.

Claim 6. (Original) A process as claimed in claim 5, wherein the solvent is selected from aliphatic or aromatic chlorides, aromatic hydrocarbons, esters of a carboxylic acid, alkyl carbonates, alkanols, alkyl or cycloalkyl ketones, or mixtures thereof.

- Claim 7. (Currently Amended) A process as claimed in claims 1 for the preparation of a biologically active compound containing a sulfinyl or sulfonyl group, the process comprising:
- a) oxidation of an intermediate containing at least one thioether to at least one sulfoxide or sulfone by treatment of the at least one thioether with an oxidizing amount of s-phthalimidoperhexanoic acid or

RPP/126037.1

Application Serial No.: 10/801,608 Inventor(s): Allegrini et al.

Attorney Docket No.: 100506-00023

b) oxidation of an intermediate containing at least one sulfoxide to at least one sulfone by treatment of the at least one sulfoxide group with an oxidizing amount of ε-phthalimidoperhexanoic acid.

Claim 8. (Currently Amended) A process as claimed in claim 7, wherein the biologically active compound is selected from the group consisting of modafinil, modafinil sulfone, sulindac, sulindac-sulfone, dapsone, emeprazole, panteprazole, lansoprazole, timoprazole, picoprazole, raboprazole and exemeprazole 2-[(diphenylmethyl)sulfinyl]acetamide (Modafinil); 2-[(diphenylmethyl)sulfonyl]acetamide (Modafinil-sulfone); (Z)-5-fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1Hindene-3-acetic acid (Sulindac); (Z)-5-fluoro-2-methyl-1-[[4-(methylsulfonyl)phenyl]methylene]-1H-indene-3-acetic acid (Sulindac-sulfone); 4.4'sulfonylbenzenamine (Dapsone); 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2pyridinyl)methyl]sulfinyl]-1H-benzimidazole (Omeprazole); 5-difluoromethoxy-2[[3,4dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (Pantoprazole); 2-[[[methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (Lansoprazole); 2-[[(2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (Timoprazole); 5-ethoxycarbonyl-6methyl-2[[(3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (Picoprazole); 2-[[[3methyl-4-(3-methoxypropoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (Rabeprazole); (S)-5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (Exomeprazole).

- Claim 9. (Original) A process as claimed in claim 1, wherein the intermediate compound containing a thioether group is selected from the group consisting of:
 - 1-(4-fluorophenyl)-2-(4-methylthio-phenyl)-ethanone;
- (Z)-5-fluoro-2-methyl-l-[[4-(methylthio)-phenyl]methylene]-1H-indene-3-acetic acid:
 - 2-[(diphenylmethyl)thio]acetic acid;
 - 2-[(diphenylmethyl)thio]acetamide;
 - 4,4'-thiobisbenzenamine:

Application Serial No.: 10/801,608 Inventor(s): Allegrini et al.

Attorney Docket No.: 100506-00023

5-methoxy-2 [[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazole);

5-difluoromethoxy)-2-[(4-chloro-3-methoxy-2-pyridinyl)methyl]thio-1H-benzimidazole;

5-difluoromethoxy-2[[3,4-dimethoxy-2-pyridinyl)methyl]thio]-1H-benzimidazole;

2-[[[methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]thio]-1H-benzimidazole;

2-[[(2-pyridinyl)methyl]thio]-1H-benzimidazole;

5-ethoxycarbonyl-6-methyl-2 [[(3-methyl-2-pyridinyl)methyl]thio]-1H-benzimidazole;

2-[[[3-methyl-4-(3-methoxypropoxy)-2-pyridinyl]methyl]thio]-1H-benzimidazole; and

(S)-(5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazole).

Claim 10. (Currently Amended) A process as claimed in claim 1, wherein the intermediate compound containing a sulfoxide group is selected from the group consisting of sulindac, modafinil, (Z)-5-fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid (Sulindac), 2-[(diphenylmethyl)sulfinyl]acetamide (Modafinil),1-(4-fluorophenyl)-2-(4-methylsulfinyl-phenyl)-ethanone and 2-[(diphenylmethyl)sulfinyl]acetic acid.